What is Iberogast and how does it work?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is Iberogast and How Does It Work

Iberogast (also known as STW5) is a multi-herbal liquid formulation containing nine plant extracts that treats functional dyspepsia and irritable bowel syndrome through multiple mechanisms including gastric relaxation, enhanced antral motility, intestinal secretion, and reduced visceral hypersensitivity.

Composition and Formulation

Iberogast is a fixed combination of hydroethanolic herbal extracts that has been available for over five decades 1. The original formulation (STW5) contains nine herbal components, though a refined six-component version (STW5-II) has also been developed 1. This phytomedicine represents a multitarget therapeutic approach addressing the heterogeneous pathophysiology of disorders of gut-brain interaction 1.

Mechanisms of Action

Gastric Motor Effects

Iberogast demonstrates region-dependent effects on gastric function:

  • Proximal stomach: Increases gastric relaxation and proximal gastric volume (from 104 mL to 174 mL in healthy subjects), facilitating meal accommodation 2
  • Antral region: Stimulates antral contractility and increases the motility index of antral pressure waves, particularly in the first 60 minutes after administration 2
  • No significant effect on pyloric or duodenal pressures 2

These complementary actions on fundic relaxation and antral motility likely contribute to symptom relief in functional dyspepsia 2.

Intestinal Secretory Effects

STW5 acts as a prosecretory agent in the human intestine through both direct epithelial actions and enteric nervous system activation 3:

  • Induces dose-dependent increases in ion secretion via chloride channels
  • Activates both CFTR (cystic fibrosis transmembrane conductance regulator) and calcium-dependent chloride channels (ClCa) 3
  • Stimulates 51% of human submucous neurons, increasing spike discharge 3
  • The secretory effect is partially mediated through enteric neurons, as demonstrated by tetrodotoxin suppression 3

This prosecretory mechanism makes STW5 potentially beneficial for constipation-predominant conditions 3.

Visceral Hypersensitivity Reduction

In patients with IBS and bloating, STW5 significantly reduces symptom perception during colonic gas challenge (symptom score increment 3.2 vs. 4.0 with placebo, p=0.035) without affecting gas retention or evacuation patterns 4. This indicates a primary effect on visceral sensitivity rather than motility alone 4.

In patients with functional dyspepsia and reflux symptoms, STW5 increases the lag time to acid perception in those with reflux esophagitis (p=0.042), suggesting reduced esophageal hypersensitivity 5.

Additional Mechanisms

The formulation targets multiple pathophysiological mechanisms simultaneously 1:

  • Anti-inflammatory effects
  • Mucosal barrier function enhancement
  • Modulation of gut-brain axis signaling

Clinical Evidence

Functional Dyspepsia

STW5 moderately improves global dyspeptic symptoms compared to placebo at 28-56 days (MD -2.64,95% CI -4.39 to -0.90), though the certainty of evidence is very low 6. The improvement rate is also higher with STW5 versus placebo at 4-8 weeks (RR 1.55,95% CI 0.98 to 2.47) 6.

IBS and Reflux Overlap

In patients with functional dyspepsia and concurrent reflux symptoms, STW5 reduces GERD and regurgitation subscale scores (p=0.049 and p=0.007 respectively) 5. In a subgroup with pH-metry confirmed GERD, STW5 significantly reduced total acidic reflux events (p=0.028) 5.

Gas-Related Symptoms

STW5 improves colonic gas tolerance in IBS patients with bloating, allowing complete return of symptoms and distension to baseline after gas evacuation, whereas placebo-treated patients maintain elevated symptoms (p=0.048) and distension (p=0.016) 4.

Safety Profile

There is little to no difference in adverse event rates between STW5 and placebo (RR 0.92,95% CI 0.52 to 1.64) 6. The medication has a favorable safety profile with over five decades of clinical use 1.

Clinical Positioning

Iberogast fills therapeutic gaps in functional dyspepsia and IBS by simultaneously targeting motility disorders, visceral hypersensitivity, inflammation, and barrier dysfunction 1. It represents an evidence-based phytomedicine option particularly valuable for patients with overlapping symptoms or those seeking alternatives to conventional pharmacotherapy 1, 7.

Common Pitfalls to Avoid

  • Do not expect immediate symptom relief; clinical trials demonstrate efficacy at 4-8 weeks of treatment
  • The medication works through multiple mechanisms, so it may benefit patients who have failed single-target therapies
  • Consider STW5 particularly for patients with overlapping dyspepsia-IBS phenotypes or those with both upper and lower GI symptoms 1

References

6
Research

Non-Chinese herbal medicines for functional dyspepsia.

The Cochrane database of systematic reviews, 2023

Related Questions

Does consumption of guava exacerbate irritable bowel syndrome?
Is oregano oil effective for treating irritable bowel syndrome (IBS)?
Why is subcutaneous heparin being held in a patient with a history of gastrointestinal bleeding who has a pulmonary embolism?
What is the appropriate treatment for propoxur poisoning?
What is the recommended diagnostic approach and treatment regimen for human brucellosis?
What distinguishes post‑traumatic repetitive awakenings with nightly anxiety from nightmares?
In a patient with atrial fibrillation who requires apixaban (Eliquis), how should dual antiplatelet therapy be managed after recent coronary stent placement?
What is multifocal motor neuropathy and what are the recommended treatments?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.